北京航天长峰股份有限公司关于与 航天科工财务有限责任公司开展 关联交易事项的持续风险评估报告 北京航天长峰股份有限公司（以下简称"航天长峰"或"公司"） 按照《上海证券交易所上市公司自律监管指引第 5 号——交易与关联 交易》的要求，公司通过查验航天科工财务有限责任公司（以下简称 "财务公司"）《金融许可证》、《企业法人营业执照》等证件资料，并 审阅了财务公司资产负债表、利润表、现金流量表等财务报表，对财 务公司的经营资质、业务和风险状况进行了评估，现将风险评估情况 报告如下： 一、财务公司基本情况 航天科工财务有限责任公司经中国银行保险监督管理委员会批 准（金融许可证编号：L0009H211000001）、北京市市场监督管理局登 记注册（统一社会信用代码：911100007109288907）的非银行金融机 构，依法接受银保监会的监督管理。 注册资本：438,489 万元人民币 法定代表人：王厚勇 注册地址：北京市海淀区紫竹院路 116 号 B 座 12 层 成立日期：2001 年 10 月 10 日 财务公司在银保监会核准的经营范围内开展业务，目前，经营范 围主要包括：对成员单位办理财务和融资顾问、信用鉴 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600855 证券简称：航天长峰 公告编号：2023-054 北京航天长峰股份有限公司 十届二次监事会会议决议公告 审核意见：公司严格遵照中国证监会、上海证券交易所及公司 《募集资金管理办法》关于上市公司募集资金使用的相关规定，不 存在违法违规使用募集资金的行为，同意该专项报告。 此议案表决结果如下：3 票同意，0 票弃权，0 票反对。 三、审议通过了公司关于 2023 年度中期利润分配预案的议案。 鉴于公司 2023 年上半年实施再融资计划与 2022 年度利润分配 预案存在一定程度的冲突，公司董事会临时调整了 2022 年度利润分 配预案，基于公司 2023 年半年度业绩实现情况及结合公司 2022 年 度利润分配预案的相关承诺，董事会建议公司 2023 年中期的利润分 配预案为：以 2023 年中期利润分配实施股权登记日总股本为分配基 数，预计每 10 股派发现金红利 0.035 元（含税）人民币，共计拟 向全体股东派发现金红利 1,672,921.16 元 ...

一、获得补助的基本情况 证券代码：600855 证券简称：航天长峰 公告编号：2023-051 北京航天长峰股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 二、补助的类型及其对上市公司的影响 根据《企业会计准则第 16 号-政府补助》有关规定，公司将上述补助认定 为与收益相关的政府补助，其中第 1、2、3、4、8 项补助合计 84.50 万元计入 递延收益，第 5、6、7、9、10 项补助合计 132.88 万元计入其他收益，最终的 会计处理以及对公司损益的影响情况以审计机构年度审计确认后的结果为准， 敬请广大投资者注意投资风险。 特此公告。 近日，经北京航天长峰股份有限公司（以下简称：本公司）相关部门确 认，本公司及所属子公司自 2023 年 5 月 24 日至 2023 年 8 月 18 日收到的政府 补助资金共计 2，173，828.01 元，占公司 2022 年度经审计归属于上市公司股 东的净利润的 39.68%，具体情况如下： | 序 | 获得时间 | 发放单位 | 发放事 ...

证券代码：600855 证券简称：航天长峰 公告编号：2023-052 北京航天长峰股份有限公司关于 参股子公司清算注销完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、参股子公司注销情况概述 2023 年 8 月 18 日，公司收到昆明市工商行政管理局核发的《准 予注销登记通知书》，准予云南 CY 航天注销登记。截至本公告披露日， 云南 CY 航天工商注销登记手续已办理完毕。 二、参股子公司清算注销完成对公司的影响 云南 CY 航天作为公司参股子公司，不纳入公司合并报表范围， 本次工商注销完成不会对公司业务发展和持续盈利能力产生影响，不 存在损害公司及全体股东特别是中小股东利益的情形。 特此公告。 北京航天长峰股份有限公司 董事会 2023 年 8 月 22 日 北京航天长峰股份有限公司（以下简称"公司"）于 2020 年 6 月 3 日召开十一届二次董事会，审议通过了《公司关于参股子公司清 算注销的议案》，同意公司参股子公司云南 CY 航天数控机床有限公司 （以下简称:云南 CY 航天）进行清算注销。具 ...

证券代码：600855 证券简称：航天长峰 公告编号：2023-034 北京航天长峰股份有限公司关于召开 2022 年年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （https://www.cs.com.cn/roadshow/） 会议召开方式：网络方式 问题征集方式：投资者可于2023年5月15日中午12:00前将相关问 题通过电子邮件的形式发送至公司董事会办公室邮箱： db@casic.com.cn。本公司将在2022年年度业绩暨现金分红说明会 （以下简称"业绩说明会"）上对投资者普遍关注的问题及2022年 度现金分红情况进行统一回答。 一、说明会类型 北京航天长峰股份有限公司（以下简称"公司"）已于2023年3 月21日披露本公司2022年年度报告，为使广大投资者更加全面深入 地了解公司经营业绩、财务状况、发展战略等情况，公司定于2023 年5月18日下午14:00-16:00以网络方式召开2022年年度业绩说明 会，就投资者普遍关注的问题及2022年度现金分红情况 ...

Financial Performance - The company reported a revenue of CNY 207.29 million for Q1 2023, a decrease of 9.97% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY -44.52 million, reflecting a decline of CNY 3 million year-on-year[6]. - Total operating revenue for Q1 2023 was CNY 207,288,226.59, a decrease of 10% compared to CNY 230,237,597.60 in Q1 2022[22]. - Net loss for Q1 2023 was CNY 47,593,980.85, compared to a net loss of CNY 46,092,594.70 in Q1 2022, indicating a slight increase in losses[24]. - The company reported a total comprehensive loss of CNY 47,593,980.85 for Q1 2023, compared to a total comprehensive loss of CNY 46,092,594.70 in Q1 2022[24]. Revenue Breakdown - High-end medical equipment business revenue increased significantly to CNY 64 million, a growth of 2,080.68% year-on-year, driven by new orders and increased sales volume[6]. - Military electronics business revenue decreased to CNY 133 million, down 16.22% year-on-year, primarily due to changes in customer demand and lower delivery volumes[6]. - Public safety business revenue fell to CNY 8 million, a decline of 87.96% year-on-year, attributed to project settlement delays despite winning several key projects[6]. Cash Flow and Management - The company reported a net cash flow from operating activities of CNY -80.78 million, with a focus on optimizing cash management[11]. - Operating cash flow for Q1 2023 was negative at -80,778,295.32 RMB, an improvement from -300,865,490.95 RMB in Q1 2022, indicating a 73% reduction in cash outflow[28]. - Total cash inflow from operating activities was 329,399,899.94 RMB, compared to 306,776,337.41 RMB in the same period last year, reflecting an increase of approximately 7.4%[28]. - Cash outflow from operating activities decreased to 410,178,195.26 RMB from 607,641,828.36 RMB, marking a 32.5% reduction[28]. Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3.81 billion, down 5.35% from the end of the previous year[6]. - The company's total liabilities decreased to CNY 1,956,123,907.81 in Q1 2023 from CNY 2,130,041,980.85 in Q1 2022, a reduction of about 8.1%[22]. - Total equity decreased to CNY 1,850,198,874.10 in Q1 2023 from CNY 1,891,449,144.11 in Q1 2022, reflecting a decline of approximately 2.2%[22]. - The company's total liabilities decreased to RMB 2,572,375,314.59 from RMB 2,745,195,988.27, indicating a reduction of approximately 6.29%[18]. Research and Development - Research and development expenses for Q1 2023 were CNY 17,979,548.47, slightly down from CNY 18,800,614.77 in Q1 2022, indicating a decrease of about 4.4%[23]. - The company incurred research and development expenses of ¥7,964,051.69 in Q1 2023, down from ¥11,709,436.27 in Q1 2022, indicating a decrease of approximately 32%[35]. Future Outlook - The company plans to enhance innovation capabilities and focus on new product development and market expansion to improve overall profitability[7]. - The company has not reported any significant new product developments or market expansions during the reporting period[15].

Financial Performance - The net profit attributable to the parent company for 2022 was CNY 5,477,761.49, with a cumulative profit available for distribution to shareholders at CNY 105,489,616.30[5]. - The company reported a revenue of 1.802 billion RMB in 2022, a decrease of 35.30% compared to 2.785 billion RMB in 2021[28]. - Net profit attributable to shareholders was 0.055 billion RMB, down 95.33% from 0.117 billion RMB in the previous year[28]. - The basic earnings per share decreased to 0.0125 RMB, a decline of 95.33% from 0.2677 RMB in 2021[27]. - The total assets decreased by 8.32% to 4.021 billion RMB from 4.386 billion RMB in 2021[26]. - The company achieved an annual revenue of 1.802 billion RMB and a net profit attributable to shareholders of 5.5 million RMB in 2022[38]. - The company achieved operating revenue of 1.802 billion RMB, a decrease of 35.30% compared to the previous year[48]. - Net profit for the period was 32 million RMB, with net profit attributable to shareholders of 5.5 million RMB[48]. Business Segments and Strategy - The company has restructured its main business segments into three major areas: high-end medical equipment, military electronics, and public safety, aiming to enhance resource collaboration and optimize industry layout[9]. - The company emphasizes high-quality development and focuses on core industries, aiming to strengthen its core competitiveness, marketing capabilities, and profitability[9]. - The high-end medical equipment sector saw a revenue decline of 78.16% and a net profit drop of 142.78% compared to the previous year[28]. - The military electronics sector's revenue decreased by 2.47%, with net profit declining by 34.73%[28]. - The public safety sector's revenue fell by 47.83%, while net profit increased by 103.02% due to improved asset quality management[28]. - The company is positioned in the high-end medical equipment, military electronics, and public safety sectors, benefiting from supportive policies and market demand[41]. - The company is focusing on expanding its market presence in the domestic military electronics sector and enhancing collaboration with key research institutions[38]. Research and Development - The company plans to increase investment in R&D for key products like high-end domestic ventilators and ECMO systems to enhance market competitiveness[28]. - The company completed 102 invention patent applications and received 4 provincial and ministerial-level science and technology progress awards during the year[39]. - The company is advancing the ECMO system research and development project and has successfully launched upgraded ventilator products[39]. - The company is enhancing its digital capabilities by promoting digital manufacturing for high-end medical devices and developing a series of controllable digital software products[40]. - Total R&D investment amounted to ¥116,158,424.56, representing 6.45% of operating income[66]. - The number of R&D personnel accounted for 22.65% of the total workforce[66]. - Research and development expenses fell by 25.17% to 112.76 million RMB, as new projects had just commenced and had not yet entered a high investment phase[51]. Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm, Zhihong[4]. - The company has committed to ensuring the authenticity, accuracy, and completeness of the annual report, with all board members present at the meeting[4]. - The company has optimized its governance structure and completed the establishment of necessary party organizations and board systems across subsidiaries[40]. - The company has established a long-term mechanism for internal control, conducting annual audits and evaluations of control deficiencies[138]. - The company has implemented a comprehensive internal control system covering all business areas, with subsidiaries establishing risk control committees and management systems[138]. - The company has strengthened its compliance governance system, ensuring that major operational decisions are effectively monitored and controlled[140]. Shareholder and Management Information - The total number of shares held by the board members at the end of the reporting period remained unchanged at 1,075,100 shares[105]. - The total pre-tax remuneration for the board members during the reporting period amounted to 5.71 million yuan[105]. - The chairman, Xiao Haichao, received a total pre-tax remuneration of 712,100 yuan[105]. - The president, Su Zihua, received a total pre-tax remuneration of 851,300 yuan[105]. - The company appointed new executives, including a female vice president and a female CFO, both starting their terms in January 2023[105]. - The company has a structured approach to governance, ensuring compliance with relevant laws and regulations[102]. Environmental and Social Responsibility - The company invested 50 million yuan in environmental protection during the reporting period[144]. - The company processed a total of 3.5 tons of hazardous waste in 2022, primarily from packaging and cleaning operations[144]. - The company reduced carbon emissions by 53 tons through various measures, including the promotion of photovoltaic technology and the use of energy-efficient equipment[148]. - The distributed photovoltaic power station generated approximately 32,400 kWh in 2022, leading to a reduction of about 10 tons of CO2 emissions[149]. - The company donated CNY 15,000 to a local charity, benefiting 10 individuals[150]. Legal and Financial Matters - The company is involved in a significant lawsuit with ongoing developments, including a mediation agreement confirming payments and obligations[168]. - The company reported actual sales-related related party transactions of 95.2098 million yuan, which is 31.74% of the projected 300 million yuan[171]. - The company has a financial relationship with the financial company of the controlling group, with a total credit of 90 million yuan and an actual occurrence of 0.038021 million yuan[177]. - The company reported a total deposit amount of 789.6518 million yuan with a range of interest rates from 0.35% to 1.95%[175]. - The company has established a financial cooperation agreement with the Aerospace Science and Industry Financial Company, which includes various financial services[178].

Financial Performance - The net profit attributable to the parent company for 2019 was CNY 42,693,776.59, with a cumulative profit available for distribution to shareholders of CNY 116,681,790.12[7]. - The proposed cash dividend for 2019 is CNY 0.30 per 10 shares, totaling CNY 13,187,732.61, which accounts for 30.89% of the net profit attributable to the parent company[7]. - The company's operating revenue for 2019 was approximately ¥2.59 billion, representing a 10.00% increase compared to 2018[24]. - Net profit attributable to shareholders decreased by 58.02% to approximately ¥42.69 million, while the net profit after deducting non-recurring gains and losses dropped by 158.70%[24]. - The basic earnings per share decreased by 58.74% to ¥0.1076, with diluted earnings per share reflecting the same figure[25]. - The weighted average return on equity fell to 2.98%, a decrease of 4.81 percentage points compared to 2018[25]. - The company reported a net profit for the reporting period of 103 million RMB, with the net profit attributable to shareholders amounting to 42.69 million RMB[57]. - The company reported a net profit of -2,244.69 million CNY for 2019, compared to a profit of 248.58 million CNY in 2018, indicating a significant decline[89]. - The company achieved a net profit of 3,187.55 million yuan for the year ending December 31, 2019[111]. - The company reported a net profit of 1,702.15 million yuan for the year ending December 31, 2019[112]. Cash Flow and Financial Management - The net cash flow from operating activities increased by 480.27% to approximately ¥250.18 million, attributed to improved collection of accounts receivable[28]. - In the first half of the year, the company's operating cash flow was negative at -28,494.36 million CNY, with a net profit attributable to the parent company of -3,506.24 million CNY[33]. - The operating cash flow and net profit began to increase in the third quarter, particularly in the fourth quarter, due to increased project progress and cash collection[33]. - The company achieved an annual operating cash flow of 250 million CNY in 2019, indicating a strong cash flow performance for the year[33]. - The company plans to extend payment terms through negotiations with suppliers, which may further enhance cash flow management[33]. - The cash flow from investment income decreased by 73.83% to 141.78 million CNY, mainly due to reduced returns from bank financial products of a subsidiary[75]. - The total amount of cash absorbed from investments was 30 million CNY, a decline of 74.83% compared to the previous year, due to last year's fundraising from mergers and acquisitions[75]. - The company’s cash flow is influenced by the nature of its clients, primarily government departments and large enterprises, which have lengthy internal payment approval processes[34]. Risk Management and Compliance - The company has disclosed potential risks related to future development in the report, urging investors to be aware of investment risks[9]. - The report emphasizes the importance of accurate financial reporting and the responsibilities of the board and management[4]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[9]. - The company has not violated decision-making procedures in providing guarantees to external parties[9]. - The company is facing risks related to technological innovation and the need to adapt to changing business models in the security technology sector[102]. - The company is addressing management risks associated with business expansion by improving its internal control management system[101]. Business Expansion and Market Presence - The company plans to continue expanding its market presence while managing costs and enhancing R&D efforts to improve competitiveness[28]. - The company has established over 150 branches and offices across 31 provincial-level regions in China, enhancing its regional marketing network[48]. - The company has expanded its business segments from three to four, adding a power supply segment after acquiring 100% of Aerospace Chaoyang Power Supply[43]. - The company is actively involved in national-level technology support projects, further solidifying its position in the industry[50]. - The company plans to expand its market share in the medical device sector and enhance its product promotion and sales efforts[97]. - The company is exploring potential mergers and acquisitions to bolster its market presence and drive revenue growth[115]. Research and Development - Research and development expenses increased by 56.49% year-on-year, totaling 74.49 million RMB, driven by increased investment in R&D[59]. - The company applied for 189 invention patents during the year, with 8 patents granted and 2 utility model patents authorized[56]. - The company is focusing on increasing R&D investments to improve core business capabilities, despite facing operational losses in some subsidiaries[90]. - The company is investing $50 million in R&D for new technologies aimed at enhancing user experience[1]. - The company has allocated 200 million for research and development in 2020, focusing on innovative solutions to improve operational efficiency[200]. Strategic Acquisitions - The company completed the acquisition of 100% equity in Aerospace Chaoyang Power through a share issuance, which was finalized on December 24, 2019[24]. - The company completed the acquisition of 100% equity in Aerospace Chaoyang Power, making it a wholly-owned subsidiary[167]. - The company completed a strategic acquisition, enhancing its capabilities in the tech sector, valued at $200 million[196]. - A strategic acquisition of a smaller tech firm is in progress, which is anticipated to enhance the company's technological capabilities and product offerings[200]. Shareholder and Stock Information - The company has maintained a consistent cash dividend policy since the revision of its articles of association in October 2014[104]. - The company has reported a decrease of 1,034,900 shares held by domestic natural persons, resulting in a total of 9,518,690 shares[163]. - The company has issued new shares amounting to 10,817,200, which is 77.5% of the total shares[163]. - The company completed a share repurchase and cancellation of 127,949 shares due to unmet performance commitments from a subsidiary[173]. - The company plans to unlock 44,738,297 shares held by China Aerospace Science and Technology Group in December 2022[179]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[197]. - The company has set a future outlook with a revenue target of 1.8 billion for 2020, indicating a projected growth of 20%[200]. - Overall, the company remains optimistic about future growth, with a commitment to sustainable practices and innovation[196].

2017 年第三季度报告 公司代码：600855 公司简称：航天长峰 北京航天长峰股份有限公司 2017 年第三季度报告 1 / 23 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 8 | | 四、 | 附录 | 11 | 2017 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人史燕中、主管会计工作负责人刘磊及会计机构负责人（会计主管人员）范小丽保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 23 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 1,742,122,427.92 1,718,723,098.49 1.36 归属于上市公司 股东的净资产 8 ...